Biotechnology

Beigene

BeiGene 2026 Q1 Earnings Soar: Net Profit Surges 178x, Revenue Breaks 10 Billion RMB Barrier

BeiGene's Sorotorac Gets FDA Accelerated Approval, Deepening BCL-2 Layout to Mitigate Single-Product Risk

BeiGene's Brukinsa Approved by FDA

BGI Q1 Profit Surges, Revenue Breaks 10 Billion Yuan

CMBC International and DBS Maintain Buy Rating for BeiGene

Citibank Raises BeiGene's US Stock Target Price to $453

Belayzhizun (BeiJing) Q1 Earnings Exceed Expectations

BeiGene Releases Q1 2026 Financial Report and Revises Financial Guidance

Beyterzelk and Amgen Authorized Products Drive First Quarter 2026 Revenue Growth for BeiGene

BeiGene Adjusts 2026 Full-Year Operating Performance Forecast

BeiGene Secures Global Rights to Huaheng's Tri-Antibody for $20 Million

BofA Securities Notes BeiGene's Pharmaceutical Sales Growth Maintains Buy Rating

BeiGene's Wholly-Owned Subsidiary Signs Exclusive Option, License and Collaboration Agreement with Huahui Anjian

BGT Biotechnology Reports First Yearly Profit, Innovation Pharmaceuticals Reach Critical Milestone

BeiGene Announces Revenue and Net Profit for 2025

BeiGene Achieves First Annual Profit, Significant Commercial Progress

BeiGene Submits Application for Zanidatamab and BGB-A317 Combination Therapy

BeiGene's Revenue Grew by 40.2% in 2025 and Achieved Profitability

Sci-Tech Innovation Board Companies Projected Earnings Growth in 2025, Several Companies Expected to 'Delist'

BeiGene Reports First Profit in 2025 with Record Sales

OPTIMI HEALTH CORP

HCW Biologics

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

Micware

Silexion Therapeutics

GCL Global

MetaVia

MicroAlgo

Vida Global

BiomX

BGNE

LABU

IBBQ

BeOne Medicines, originally founded as BeiGene in 2010, has evolved into a global biotech company focused on making cancer treatments more accessible. Based in Basel, Switzerland, BeOne has over 12,000 employees and operates in 75 countries. Its flagship drug, Brukinsa, generated $3.9 billion in sales in 2025, contributing to total revenues of $5.3 billion and achieving net profitability for the first time. The company emphasizes efficiency in drug development and has a pipeline of over 35 clinical assets.

Pharmexec

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

iShares Biotechnology ETF

Ark Genomic Revolution ETF

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

VanEck Biotech ETF

Invesco Nasdaq Biotechnology ETF

Invesco Biotechnology & Genome ETF

BeOne Medicines

BEONE MEDICINES

<![CDATA[John Oyler: Rewiring Operations in Oncology]]>

BeOne Medicines Ltd has received accelerated U.S. FDA approval for BEQALZI (sonrotoclax), the first BCL2 inhibitor for adults with relapsed mantle cell lymphoma after prior therapies. The drug shows a 52% overall response rate and a 16% complete response rate in trials. This approval, supported by Breakthrough and Orphan designations, enhances treatment options for patients facing this aggressive lymphoma. Analysts rate BeOne stock as a Buy with a price target of HK$290.00, reflecting confidence in the company's innovative therapies for blood cancers.

Tip Ranks

VG Health

Health Care Select Sector SPDR

iShares Global Healthcare

iShares US Pharma

BeOne Wins First-in-Class U.S. FDA Nod for BCL2 Drug in Relapsed Mantle Cell Lymphoma

688235

06160

UBS Reaffirms Their Buy Rating on BeOne Medicines Ltd (6160)

businessinsider

UBS Reaffirms Their Buy Rating on BeOne Medicines Ltd (6160)

BeOne Medicines Ltd has filed a Form S-3 with the U.S. SEC to enable delayed or continuous securities offerings in the U.S. market. This move aims to enhance its access to U.S. capital markets, supporting future financing and strengthening its global investor appeal. The filing reflects BeOne's compliance with both U.S. and Hong Kong regulations, potentially broadening its funding options. The latest analyst rating for BeOne's stock (HK:6160) is a Buy, with a price target of HK$290.00.

BeOne Medicines Files Form S-3 to Expand U.S. Capital Market Access

SNSE

Senhwa Biosciences, Inc. has launched a global clinical trial for its investigational drug CX-5461, in combination with tislelizumab, targeting hard-to-treat cancers such as pancreatic and colorectal cancers. The trial aims to validate the drug's efficacy and safety, potentially attracting interest from pharmaceutical companies for licensing or acquisition. This initiative is part of Senhwa's strategy to enter the growing immuno-oncology market, which is projected to exceed $300 billion by 2035. The unique mechanism of CX-5461 may enhance tumor immunogenicity and improve patient responses to current therapies.

prnewswire

Sensei Biotherapeutics

Twist Bioscience

03:40 ETSenhwa Biosciences Launches Global Study, Targeting Breakthrough in Hard-to-Treat Cancers with CX-5461 and Tislelizumab Combination

159892

588250

520880

159316

520690

Huahui Health has entered a global exclusive option, license, and collaboration agreement with BeOne Medicines for HH160, a novel trispecific antibody for oncology immunotherapy. BeOne will pay Huahui an upfront fee of $20 million, with potential additional payments totaling up to $1.9 billion based on milestones. The agreement aims to advance HH160's development and commercialization, enhancing treatment options for cancer patients. Huahui Health, founded in 2015, focuses on innovative therapies in oncology and liver diseases, while BeOne Medicines specializes in developing cancer treatments globally.

SPDR S&P Health

GF CSI HK Innovative Drugs Industry ETF(QDII)

China Southern Hang Seng Biotech ETF(QDII)

China Universal 800 Health Care ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Bosera Hang Seng Health Care ETF(QDII)

ChinaAMC SSE STAR Biology and Medicine ETF

China Merchants CSI Biotechnology Theme ETF

Guotai CSI Bio-medicine ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Penghua SSE STAR Biology and Medicine ETF

Ping An CSI Medicine and Medical Device Innovation ETF

E Fund CSI 300 Health Care ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Yinhua CSI Innovative Drugs Industry ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Huaan Hang Seng Biotech ETF

Minsheng Royal CSI Biotechnology Theme ETF

Tianhong CNI BIOMEDICINE ETF

ICBCCS SSE STAR Biology and Medicine ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC CSI Biotechnology Theme ETF

Guotai SSE STAR Brand Name Drug ETF

E Fund CSI Biotechnology Theme ETF

ChinaAMC SSE Health Care ETF Initiating Fund

iShares US Healthcare Providers

HUA HAN HEALTH

04:21 ETHuahui Health and BeOne Medicines Enter into a Global Exclusive Option, License and Collaboration Agreement for Innovative Oncology Drug HH160

BofAS has maintained a Buy rating on BEIGENEwith a target price of HKD243.83. The company reported total drug sales in China of RMB602.4 million in February, a 17.7% increase year-over-year. Sales of self-developed and in-licensed products were RMB332.2 million and RMB269.8 million, rising 20.3% and 14.5% YoY, respectively. Notably, tislelizumab and zanubrutinib sales reached RMB244.7 million and RMB87.3 million, showing YoY growth of 14.1% and 42.6%.

AASTOCKS News

Bank of America

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

BofAS Maintains Buy on BEIGENE  with TP at HKD243.83

Ahead of the upcoming American Association for Cancer Research (AACR) annual meeting and the American Society of Clinical Oncology (ASCO) annual meeting, biopharmaceutical stocks have performed well, particularly Beigene and WuXi AppTec. Beigene is expected to achieve a net profit of $287 million in 2025, with total annual revenue of $5.343 billion, a growth of 40%. Its main product, "Tislelizumab," has performed exceptionally well in the European and American markets, driving revenue growth. The company has also achieved significant income from external licensing, with innovative drug licensing deals exceeding $60 billion in the first quarter

Stheadline

WuXi AppTec

WUXI APPTEC

Innovative drugs welcome the "going abroad" harvest period, with a surge in external licensing amounts. Beigene turns losses into profits, and WuXi AppTec sees a significant increase in orders. | Investment Pursuit

uBriGene Biosciences has partnered with Cellinfinity BIO to advance in vivo CAR-T therapy for haematologic and solid tumours. The collaboration focuses on CIB-301 and CIB-350 programmes, utilizing uBriGene’s LVV Turbo platform for GMP lentiviral vector manufacturing. CIB-301 targets solid tumours with a fully human CAR scFv, while CIB-350 addresses autoimmune diseases and haematologic malignancies. The partnership aims to reduce treatment costs and improve patient accessibility to CAR-T therapies.

Pharmaceutical Technology

SPDR S&P Health Equip

Unity Biotechnology

Boundless Bio

Mustang Bio

Bioxcel Therap

uBriGene and Cellinfinity BIO collaborate to accelerate in vivo CAR-T therapies

JPMorgan Chase & Co. reduced its stake in BeOne Medicines Ltd. by 49.1% in Q3, selling 47,002 shares, leaving it with 48,812 shares valued at $16.63 million. Other institutional investors have also adjusted their positions. Analysts have mixed ratings on the stock, with a consensus of "Moderate Buy" and an average price target of $389.18. BeOne Medicines' stock opened at $283.45, with a market cap of $31.10 billion and a P/E ratio of 112.48. The company reported earnings of $0.58 per share, missing estimates, and expects a loss of $5.82 EPS for the current year.

Market Beat

Defiance Daily Target 2X Long JPM ETF

JPMorgan Chase

JPMorgan Chase & Co. Sells 47,002 Shares of BeOne Medicines Ltd. - Sponsored ADR $ONC

Beigene(BGNE.US)

<![CDATA[John Oyler: Rewiring Operations in Oncology]]>

BeOne Wins First-in-Class U.S. FDA Nod for BCL2 Drug in Relapsed Mantle Cell Lymphoma

UBS Reaffirms Their Buy Rating on BeOne Medicines Ltd (6160)

BeOne Medicines Files Form S-3 to Expand U.S. Capital Market Access

03:40 ETSenhwa Biosciences Launches Global Study, Targeting Breakthrough in Hard-to-Treat Cancers with CX-5461 and Tislelizumab Combination

04:21 ETHuahui Health and BeOne Medicines Enter into a Global Exclusive Option, License and Collaboration Agreement for Innovative Oncology Drug HH160

BofAS Maintains Buy on BEIGENE with TP at HKD243.83

Innovative drugs welcome the "going abroad" harvest period, with a surge in external licensing amounts. Beigene turns losses into profits, and WuXi AppTec sees a significant increase in orders. | Investment Pursuit

uBriGene and Cellinfinity BIO collaborate to accelerate in vivo CAR-T therapies

JPMorgan Chase & Co. Sells 47,002 Shares of BeOne Medicines Ltd. - Sponsored ADR $ONC